Aarhus University Seal / Aarhus Universitets segl

Isa Niemann

Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. / Bolze, Pierre-Adrien; Attia, Jocelyne; Massardier, Jérôme; Seckl, Michael J; Massuger, Leon; van Trommel, Nienke; Niemann, Isa; Hajri, Touria; Schott, Anne-Marie; Golfier, François; EOTTD group.

I: European journal of cancer (Oxford, England : 1990), Bind 51, Nr. 13, 09.2015, s. 1725-31.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Bolze, P-A, Attia, J, Massardier, J, Seckl, MJ, Massuger, L, van Trommel, N, Niemann, I, Hajri, T, Schott, A-M, Golfier, F & EOTTD group 2015, 'Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases', European journal of cancer (Oxford, England : 1990), bind 51, nr. 13, s. 1725-31. https://doi.org/10.1016/j.ejca.2015.05.026

APA

Bolze, P-A., Attia, J., Massardier, J., Seckl, M. J., Massuger, L., van Trommel, N., Niemann, I., Hajri, T., Schott, A-M., Golfier, F., & EOTTD group (2015). Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. European journal of cancer (Oxford, England : 1990), 51(13), 1725-31. https://doi.org/10.1016/j.ejca.2015.05.026

CBE

Bolze P-A, Attia J, Massardier J, Seckl MJ, Massuger L, van Trommel N, Niemann I, Hajri T, Schott A-M, Golfier F, EOTTD group. 2015. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. European journal of cancer (Oxford, England : 1990). 51(13):1725-31. https://doi.org/10.1016/j.ejca.2015.05.026

MLA

Vancouver

Bolze P-A, Attia J, Massardier J, Seckl MJ, Massuger L, van Trommel N o.a. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. European journal of cancer (Oxford, England : 1990). 2015 sep;51(13):1725-31. https://doi.org/10.1016/j.ejca.2015.05.026

Author

Bolze, Pierre-Adrien ; Attia, Jocelyne ; Massardier, Jérôme ; Seckl, Michael J ; Massuger, Leon ; van Trommel, Nienke ; Niemann, Isa ; Hajri, Touria ; Schott, Anne-Marie ; Golfier, François ; EOTTD group. / Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. I: European journal of cancer (Oxford, England : 1990). 2015 ; Bind 51, Nr. 13. s. 1725-31.

Bibtex

@article{55f28c1317ed4fdaacff26a4d88dd244,
title = "Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases",
abstract = "Gestational trophoblastic disease (GTD) is a spectrum of cellular proliferations arising from trophoblast. Their invasive and metastatic potential sometimes requires chemotherapy and/or surgery. Current management is generally associated with favourable prognosis. Therefore, treatments must be chosen according to the desire for further childbearing of each patient. The European Organisation for Treatment of Trophoblastic Diseases (EOTTD) is dedicated to optimise diagnosis, treatment, follow-up and research in GTD by bringing together knowledge of clinicians and researchers from 29 countries working in the field of GTD in Europe. This study assessed the level of agreement among an expert panel of the EOTTD in order to rationalise the management of patients in Europe. The RAND/UCLA Appropriateness Method was used to combine the best available scientific evidence with the collective judgment of experts to yield a statement regarding the appropriateness of performing a procedure at the level of patient-specific symptoms, medical history and test results. There was an agreement for 54 statements while the experts showed a disagreement for two statements. As there is little evidence from randomised trials on which to base recommendations about management of GTD, many of these recommendations are based on expert opinion derived from changes in management fact that have improved outcomes from nearly 100% fatality to nearly 100% cure rates. However, a large agreement among experts is invaluable to the individual clinician who is struggling to decide whether a fertility-sparing treatment of hydatidiform mole or a low-risk GTN can be chosen and how it must be conducted.",
author = "Pierre-Adrien Bolze and Jocelyne Attia and J{\'e}r{\^o}me Massardier and Seckl, {Michael J} and Leon Massuger and {van Trommel}, Nienke and Isa Niemann and Touria Hajri and Anne-Marie Schott and Fran{\c c}ois Golfier and {EOTTD group}",
note = "Copyright {\textcopyright} 2015 Elsevier Ltd. All rights reserved.",
year = "2015",
month = sep,
doi = "10.1016/j.ejca.2015.05.026",
language = "English",
volume = "51",
pages = "1725--31",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",
number = "13",

}

RIS

TY - JOUR

T1 - Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases

AU - Bolze, Pierre-Adrien

AU - Attia, Jocelyne

AU - Massardier, Jérôme

AU - Seckl, Michael J

AU - Massuger, Leon

AU - van Trommel, Nienke

AU - Niemann, Isa

AU - Hajri, Touria

AU - Schott, Anne-Marie

AU - Golfier, François

AU - EOTTD group

N1 - Copyright © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/9

Y1 - 2015/9

N2 - Gestational trophoblastic disease (GTD) is a spectrum of cellular proliferations arising from trophoblast. Their invasive and metastatic potential sometimes requires chemotherapy and/or surgery. Current management is generally associated with favourable prognosis. Therefore, treatments must be chosen according to the desire for further childbearing of each patient. The European Organisation for Treatment of Trophoblastic Diseases (EOTTD) is dedicated to optimise diagnosis, treatment, follow-up and research in GTD by bringing together knowledge of clinicians and researchers from 29 countries working in the field of GTD in Europe. This study assessed the level of agreement among an expert panel of the EOTTD in order to rationalise the management of patients in Europe. The RAND/UCLA Appropriateness Method was used to combine the best available scientific evidence with the collective judgment of experts to yield a statement regarding the appropriateness of performing a procedure at the level of patient-specific symptoms, medical history and test results. There was an agreement for 54 statements while the experts showed a disagreement for two statements. As there is little evidence from randomised trials on which to base recommendations about management of GTD, many of these recommendations are based on expert opinion derived from changes in management fact that have improved outcomes from nearly 100% fatality to nearly 100% cure rates. However, a large agreement among experts is invaluable to the individual clinician who is struggling to decide whether a fertility-sparing treatment of hydatidiform mole or a low-risk GTN can be chosen and how it must be conducted.

AB - Gestational trophoblastic disease (GTD) is a spectrum of cellular proliferations arising from trophoblast. Their invasive and metastatic potential sometimes requires chemotherapy and/or surgery. Current management is generally associated with favourable prognosis. Therefore, treatments must be chosen according to the desire for further childbearing of each patient. The European Organisation for Treatment of Trophoblastic Diseases (EOTTD) is dedicated to optimise diagnosis, treatment, follow-up and research in GTD by bringing together knowledge of clinicians and researchers from 29 countries working in the field of GTD in Europe. This study assessed the level of agreement among an expert panel of the EOTTD in order to rationalise the management of patients in Europe. The RAND/UCLA Appropriateness Method was used to combine the best available scientific evidence with the collective judgment of experts to yield a statement regarding the appropriateness of performing a procedure at the level of patient-specific symptoms, medical history and test results. There was an agreement for 54 statements while the experts showed a disagreement for two statements. As there is little evidence from randomised trials on which to base recommendations about management of GTD, many of these recommendations are based on expert opinion derived from changes in management fact that have improved outcomes from nearly 100% fatality to nearly 100% cure rates. However, a large agreement among experts is invaluable to the individual clinician who is struggling to decide whether a fertility-sparing treatment of hydatidiform mole or a low-risk GTN can be chosen and how it must be conducted.

U2 - 10.1016/j.ejca.2015.05.026

DO - 10.1016/j.ejca.2015.05.026

M3 - Journal article

C2 - 26092638

VL - 51

SP - 1725

EP - 1731

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 13

ER -